PharmaShots | Incisive News in 3 Shots

Subscribe Now

Macroglobulinemia

$BeiGene's Brukinsa (zanubrutinib) Receives the NMPA's Approval for Relapsed or Refractory Waldenström's Macroglobulinemia$

BeiGene's Brukinsa (zanubrutinib) Receives the NMPA's Approval for Relapsed or Refractory Waldenström's Macroglobulinemia

June 21, 2021

BeiGene Reports the US FDA's Acceptance of sNDA for Brukinsa (zanubrutinib) in Waldenström's Macroglobulinemia

BeiGene Reports the US FDA's Acceptance of sNDA for Brukinsa (zanubrutinib) in Waldenström's Macroglobulinemia

February 18, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us